P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients
about
Antibody Drug Conjugates: Preclinical ConsiderationsHematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells.Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapyCytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.Investigational antibody-drug conjugates for hematological malignancies.Designing immunoconjugates for cancer therapy.Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug ConjugatesStrategies and challenges for the next generation of antibody-drug conjugates.Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.Encapsulation of Piper cabralanum (Piperaceae) nonpolar extract in poly(methyl methacrylate) by miniemulsion and evaluation of increase in the effectiveness of antileukemic activity in K562 cells.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein.
P2860
Q27022321-FD3B3597-D3A5-4A5D-BB58-06AB9E02C0F5Q33690881-4D277788-F779-471D-B967-3EE3673D6962Q34773994-3D95C925-E5A8-4674-84AF-BF8058C4D0F6Q35446333-0E7E893D-F7C4-40FC-A044-CD051BD731E9Q36614947-645BAC94-727E-47EF-A355-E0D150B13C78Q37349113-4FAC8415-BD7B-4E09-A76F-477F95892962Q37818256-F9C66C91-5DD5-43AB-A320-3D23CFF25D3DQ38017203-398AD34D-FF95-4A40-9370-B28EEE119CB0Q38262066-3032A16E-1101-40A5-A370-B0CFBF55F3AFQ39182945-D198DE99-A8B0-48F7-8ED6-BB43D0A381EAQ45792529-6F2BFC8C-92E8-42E0-BD11-1079A5FC0EFCQ46871150-A8DCB6F4-F47E-491F-8B60-912A79385564Q47161864-8C0FFF64-AA00-407A-AD52-625A32A866B5Q47661007-ECA6AB5F-358C-470B-A292-196D3FE0A637Q50886676-A07C813E-46F0-4C02-AECF-98EB79C5CD3E
P2860
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
P-gp activity is a critical re ...... ute myeloid leukaemia patients
@ast
P-gp activity is a critical re ...... ute myeloid leukaemia patients
@en
type
label
P-gp activity is a critical re ...... ute myeloid leukaemia patients
@ast
P-gp activity is a critical re ...... ute myeloid leukaemia patients
@en
prefLabel
P-gp activity is a critical re ...... ute myeloid leukaemia patients
@ast
P-gp activity is a critical re ...... ute myeloid leukaemia patients
@en
P2093
P2860
P356
P1433
P1476
P-gp activity is a critical re ...... ute myeloid leukaemia patients
@en
P2093
Anne-Marie Faussat
Claudia Zuany-Amorim
Elise Corre
Fanny Fava
Hamid Morjani
Jean-Pierre Marie
Jean-Yves Perrot
Ollivier Legrand
Ruoping Tang
Simy Cohen
P2860
P2888
P356
10.1186/1471-2407-9-199
P407
P577
2009-06-23T00:00:00Z
P5875
P6179
1020277867